39.65 USD
-0.10
0.25%
At close Mar 19, 4:00 PM EDT
After hours
39.65
+0.00
0.00%
1 day
-0.25%
5 days
1.35%
1 month
1.10%
3 months
-13.03%
6 months
-15.44%
Year to date
-13.41%
1 year
-12.41%
5 years
-1.69%
10 years
43.87%
 

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Employees: 5,800

0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $52.2M | Put options by funds: $35.2M

7% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 108

4% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 50

4% less capital invested

Capital invested by funds: $6.9B [Q3] → $6.6B (-$308M) [Q4]

2% less funds holding

Funds holding: 325 [Q3] → 319 (-6) [Q4]

2.58% less ownership

Funds ownership: 69.01% [Q3] → 66.43% (-2.58%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$42
6%
upside
Avg. target
$46
17%
upside
High target
$49
25%
upside

3 analyst ratings

positive
0%
neutral
100%
negative
0%
Baird
Catherine Schulte
0% 1-year accuracy
0 / 20 met price target
6%upside
$42
Neutral
Downgraded
19 Feb 2025
UBS
John Sourbeer
0% 1-year accuracy
0 / 1 met price target
21%upside
$48
Neutral
Maintained
7 Feb 2025
Morgan Stanley
Steve Beuchaw
0 / 0 met price target
25%upside
$49
Equal-Weight
Downgraded
6 Jan 2025

Financial journalist opinion

Based on 6 articles about QGEN published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
Positive
Zacks Investment Research
1 week ago
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
Neutral
Business Wire
1 week ago
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN's second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 mont.
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
Neutral
Business Wire
2 weeks ago
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This.
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
Neutral
Seeking Alpha
3 weeks ago
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Positive
The Motley Fool
3 weeks ago
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Stock splits can be undertaken for several reasons. They can bring a stock's price down to make it more affordable for a wider range of investors.
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Neutral
Business Wire
1 month ago
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world. This latest addition reflects QIAGEN's ongoing commitment to enhance its bioinformatics data infrastructure, enabling initiatives to broaden the reach and use of bioinformatics products in the Australia/.
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
Neutral
Zacks Investment Research
1 month ago
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
Neutral
Seeking Alpha
1 month ago
Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q4 2024 Earnings Conference Call February 6, 2025 10:00 AM ET Company Participants John Gilardi – Vice President, Head of Corporate Communications and Investor Relations Thierry Bernard – Chief Executive Officer Roland Sackers – Chief Financial Officer Conference Call Participants Tycho Peterson – Jefferies Michael Ryskin – Bank of America Securities Patrick Donnelly – Citi Doug Schenkel – Wolfe Research Dan Arias – Stifel Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Casey Woodring – J.P.
Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
Charts implemented using Lightweight Charts™